Shanghai, December 30, 2024 /PR Newswire/ -- WUXI APPTEC recently announced that the company has been selected for the 2024 Dow Jones Sustainability World Index (DJSI World) and the Emerging Markets Index (DJSI Emerging Markets). This marks the fourth consecutive year that WUXI APPTEC has been included in the Dow Jones Sustainability Index (DJSI), which fully demonstrates the company's firm commitment to promoting sustainable development and practicing responsible business practices.

DJSI is a globally recognized reference standard for sustainable development, measuring the sustainable performance of companies by evaluating their long-term economic, environmental, and social benefits. For investors who incorporate sustainable development into their comprehensive considerations, this index serves as an important reference. Among them, the Dow Jones Sustainability World Index represents the top 10% of the largest 2,500 companies in the S&P Global BMI index, while the Emerging Markets Index selects the top 10% of the largest 800 companies from 20 emerging markets.

The key factor for being selected for DJSI is the company's score in the S&P Global Corporate Sustainability Assessment (CSA). In November 2024, WUXI APPTEC achieved the highest score in its industry in the 2024 CSA assessment, ranking first in the "Life Sciences Tools and Services" sector globally. Notably, WUXI APPTEC is one of only four companies in its industry to be selected for the World Index and is also the only company included in the Emerging Markets Index.

"It is an honor for WUXI APPTEC to receive recognition from the Dow Jones Sustainability Index for its outstanding performance in sustainable development and empowering innovation, and to be selected again for both the Dow Jones Sustainability World Index and the Emerging Markets Index," said Mr. Hu Zhengguo, Vice Director and Chairman of the ESG Committee at WUXI APPTEC. "We will continue to adhere to sustainable development strategies, fulfill corporate social responsibilities, and assist our partners in accelerating the emergence of new drugs and breakthrough therapies for the benefit of patients worldwide."

As an innovator, a trusted partner for clients, and a contributor to the Global health industry, WUXI APPTEC has integrated the principles of ESG into every aspect of the company's Global Strategy and Operation. In 2024, WUXI APPTEC received the highest score in the CSA, ranking first in the Global "Life Sciences Tools and Services" sector; in the same year, WUXI APPTEC was rated ESG AA by MSCI for the fourth consecutive year and received "Gold" certification in EcoVadis corporate social responsibility ratings; in 2023 and 2024, the company was selected for the S&P Global Sustainable Development Yearbook and the FTSE Russell Social Responsibility Index series for two consecutive years and was simultaneously rated by Sustainalytics as a "Top Rated in Industry" and "Top Rated in Region" company; in 2024, the company joined the "United Nations Global Compact" (UNGC), pledging to support the Global Compact's ten principles; in 2023, the company joined the "Science Based Targets initiative" (SBTi) to reduce carbon emissions. WUXI APPTEC's outstanding ESG performance has also been highly recognized by global ESG rating agencies such as CDP and ISS.

About Wuxi Apptec

Wuxi Apptec (stock code: 603259.SH/2359.HK) provides integrated, end-to-end new drug research and development and production services to the global medical and life science industry, with operation bases in Asia, Europe, North America, and other regions. Through unique "CRDMO" and "CTDMO" business models, Wuxi Apptec continuously reduces the research and development threshold, helps customers enhance research and development efficiency, brings more breakthrough treatment solutions to patients, and covers a wide range of services including chemical drug research and production, biological research, preclinical testing and clinical trial development, precision medical research, testing, and production. In 2024, Wuxi Apptec was rated ESG (environment, social, and governance) AA by MSCI for the fourth consecutive year. Currently, the company's empowerment platform is carrying out research and innovation projects from over 6,000 partners in more than 30 countries around the world, dedicated to bringing more new and effective drugs to global patients, and realizing the vision of "making the world free of difficult medicines and incurable diseases" as soon as possible.